Development of next generation sequencing panel for UMOD and association with kidney disease

Caitlin Bailie, Jill Kilner, Alexander P. Maxwell, Amy McKnight

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
252 Downloads (Pure)

Abstract

Chronic kidney disease (CKD) has a prevalence of approximately 10% in adult populations. CKD can progress to end-stage renal disease (ESRD) and this is usually fatal unless some form of renal replacement therapy (chronic dialysis or renal transplantation) is provided. There is an inherited predisposition to CKD with several genetic risk markers now identified. The UMOD gene has been associated with CKD of varying aetiologies. An AmpliSeq next generation sequencing panel was developed to facilitate comprehensive sequencing of the UMOD gene, covering exonic and regulatory regions. SNPs and CpG sites in the genomic region encompassing UMOD were evaluated for association with CKD in two studies; the UK Wellcome Trust Case-Control 3 Renal Transplant Dysfunction Study (n = 1088) and UK-ROI GENIE GWAS (n = 1726). A technological comparison of two Ion Torrent machines revealed 100% allele call concordance between S5 XL™ and PGM™ machines. One SNP (rs183962941), located in a non-coding region of UMOD, was nominally associated with ESRD (p = 0.008). No association was identified between UMOD variants and estimated glomerular filtration rate. Analysis of methylation data for over 480,000 CpG sites revealed differential methylation patterns within UMOD, the most significant of these was cg03140788 p = 3.7 x 10−10.
Original languageEnglish
Article numbere0178321
JournalPLoS ONE
Volume12
Issue number6
DOIs
Publication statusPublished - 13 Jun 2017

Fingerprint

Dive into the research topics of 'Development of next generation sequencing panel for UMOD and association with kidney disease'. Together they form a unique fingerprint.

Cite this